Ralimetinib

Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc[1].

Product Specifications

CAS Number

[862505-00-8]

Product Name Alternative

LY2228820

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; p38 MAPK

Type

Reference compound

Related Pathways

Autophagy; MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ralimetinib.html

Purity

98.58

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

NC1=NC2=CC=C(C3=C(C4=CC=C(F)C=C4)N=C(C(C)(C)C)N3)N=C2N1CC(C)(C)C

Molecular Formula

C24H29FN6

Molecular Weight

420.53

Precautions

H302, H315, H319, H335

References & Citations

[1]Campbell RM, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther. 2014 Feb;13 (2) :364-74.